Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European …
J Tunon, L Badimon, ML Bochaton-Piallat… - Cardiovascular …, 2019 - academic.oup.com
Dysregulated lipid metabolism induces an inflammatory and immune response leading to
atherosclerosis. Conversely, inflammation may alter lipid metabolism. Recent treatment …
atherosclerosis. Conversely, inflammation may alter lipid metabolism. Recent treatment …
Lactiplantibacillus plantarum strains KABP011, KABP012, and KABP013 modulate bile acids and cholesterol metabolism in humans
Aims Probiotics with high bile salt hydrolase (BSH) activity have shown to promote
cardiovascular health. However, their mechanism (s) of action remain poorly understood …
cardiovascular health. However, their mechanism (s) of action remain poorly understood …
High-density lipoprotein remodelled in hypercholesterolaemic blood induce epigenetically driven down-regulation of endothelial HIF-1α expression in a preclinical …
S Ben-Aicha, R Escate, L Casaní, T Padró… - Cardiovascular …, 2020 - academic.oup.com
Abstract Aims High-density lipoproteins (HDLs) are circulating micelles that transport
proteins, lipids, and miRNAs. HDL-transported miRNAs (HDL-miRNAs) have lately received …
proteins, lipids, and miRNAs. HDL-transported miRNAs (HDL-miRNAs) have lately received …
Pig and mouse models of hyperlipidemia and atherosclerosis
GS Getz, CA Reardon - Atherosclerosis: Methods and Protocols, 2022 - Springer
Atherosclerosis is a chronic inflammatory disorder that is the underlying cause of most
cardiovascular disease. Resident cells of the artery wall and cells of the immune system …
cardiovascular disease. Resident cells of the artery wall and cells of the immune system …
CETP inhibition and HDL: what is the trial REVEALing?
L Badimon - Cardiovascular Research, 2018 - academic.oup.com
The recently published Randomized EValuation of the Effects of Anacetrapib through Lipid-
modification (REVEAL/HPS3/TIMI55) trial 1 assessed in 30 449 patients aged 50 and older …
modification (REVEAL/HPS3/TIMI55) trial 1 assessed in 30 449 patients aged 50 and older …